샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785958

세계의 세포 출발 재료 시장

Cellular Starting Materials
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 220 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 세포 출발 재료 시장은 2030년까지 50억 달러에 달할 전망

2024년에 15억 달러로 추정되는 세계의 세포 출발 재료 시장은 2024-2030년의 분석 기간에 CAGR 21.9%로 성장하며, 2030년에는 50억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 Cellular Starting Leukopaks는 CAGR 25.5%를 기록하며, 분석 기간 종료까지 34억 달러에 달할 것으로 예측됩니다. Cellular Starting Cells & Tissues 부문의 성장률은 분석 기간 중 CAGR 16.3%로 추정됩니다.

미국 시장은 추정 4억 300만 달러, 중국은 CAGR 20.5%로 성장 예측

미국의 세포 출발 재료 시장은 2024년에 4억 300만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 7억 6,080만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 20.5%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 20.5%와 18.4%로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.6%로 성장할 것으로 예측됩니다.

세계의 세포 출발 재료 시장 - 주요 동향과 촉진요인 정리

세포 출발 물질은 어떻게 생명공학에 혁명을 일으키고 있는가?

세포 출발물질은 세포치료, 재생의료, 백신 개발 등 다양한 바이오의약품 용도의 기반이 되고 있습니다. 줄기세포, 1차세포, 세포주 등을 포함한 이러한 재료는 과학 연구를 촉진하고 암, 자가면역질환, 신경퇴행성 질환 등의 질병에 대한 혁신적인 치료법을 창출하는 데 필수적입니다. 정밀의료의 급속한 확장에 따라 고품질의 잘 특성화된 세포 출발 물질에 대한 수요가 증가하고 있습니다. 생명공학과 유전공학의 발전은 세포 출발 물질의 확장성과 재현성을 더욱 향상시켰습니다. 세포배양 기술, 바이오프로세싱 기술, 냉동 보존법의 혁신은 이러한 물질의 안정성과 생존성을 보장하고 연구 및 치료 적용의 신뢰성을 높이고 있습니다. 제약 및 생명공학 분야가 계속 진화하는 가운데, 세포 출발 물질은 차세대 의료 개발에 필수적인 요소로 자리 잡고 있습니다.

세포 출발 물질에 대한 수요가 증가하는 이유는 무엇인가?

만성질환 및 유전성 질환 증가로 인해 첨단 세포 기반 치료법의 필요성이 증가하고 있으며, 이는 세포 출발 물질에 대한 수요를 촉진하고 있습니다. 연구개발자들은 특정 유전자 및 분자 경로를 표적으로 삼아 환자의 예후를 개선하는 맞춤형 치료법을 개발하기 위해 이 물질들을 활용하고 있습니다. 줄기세포 치료와 조직공학을 포함한 재생의료에 대한 관심이 높아지면서 시장 확대에 더욱 기여하고 있습니다. 또한 세포 면역 치료, 유전자 치료, 백신 제조 분야의 임상시험이 증가함에 따라 표준화되고 윤리적으로 조달된 세포 출발 물질에 대한 수요가 증가하고 있습니다. 규제기관은 세포 재료 조달에 있으며, 품질관리와 추적성을 중시하고 있으며, 이는 조달, 검증, 보관 기술의 발전으로 이어지고 있습니다. 세포 기반 연구가 새로운 치료 영역으로 확장됨에 따라 신뢰할 수 있고 확장 가능한 세포 출발 물질의 필요성은 계속 증가할 것입니다.

세포 출발 물질 시장을 주도하는 지역은?

북미는 현재 세포 출발 물질의 가장 큰 시장으로, 생명공학에 대한 활발한 투자, 탄탄한 제약 산업, 정부의 생물 의학 연구에 대한 광범위한 지원에 힘입어 성장하고 있습니다. 미국은 세포 기반 치료제 개발을 선도하고 있으며, 수많은 바이오텍 기업 및 연구기관이 새로운 세포 기반 치료제 개발에 적극 나서고 있습니다. 독일, 영국, 프랑스 등의 국가들이 세포치료 및 재생의료 분야에서 큰 진전을 이루고 있으며, 유럽이 그 뒤를 잇고 있습니다. 유럽의약품청(EMA)은 세포 기반 치료법에 대한 규제 프레임워크 구축에 적극적으로 관여하고 있으며, 이는 시장 성장을 더욱 강화하고 있습니다. 한편, 아시아태평양은 정부 구상 증가, 의료비 지출 증가, 일본, 중국, 한국에서의 임상시험 수 증가로 인해 급속한 성장을 경험하고 있습니다. 이들 지역에서는 세포 기반 연구와 치료법의 채택이 증가하고 있으며, 시장이 크게 성장할 것으로 예측됩니다.

시장 성장을 이끄는 주요 요인은 무엇인가?

세포 출발 물질 시장의 성장은 줄기세포 연구의 발전, 세포 기반 치료법의 채택 증가, 재생의료에 대한 수요 증가 등 여러 요인에 의해 이루어지고 있습니다. 세포배양 및 품질관리 프로세스에 인공지능(AI)과 자동화를 통합하여 효율성과 확장성을 향상시키고, 세포 출발 물질을 연구 및 치료 용도로 더 쉽게 사용할 수 있도록 하고 있습니다. 또한 바이오의약품 제조 능력의 확대와 정밀의료에 대한 관심이 높아지면서 고품질 세포 출발 물질에 대한 수요가 증가하고 있습니다. 연구기관, 생명공학 기업, 제약기업 간의 전략적 제휴가 증가하면서 시장 성장을 더욱 가속화하고 있습니다. 세포 기반 치료가 주류가 됨에 따라 신뢰할 수 있고 윤리적으로 조달된 세포 출발 물질에 대한 수요가 증가하여 바이오의약품 혁신의 미래를 형성할 것으로 예측됩니다.

부문

제품(Cellular Starting Leukopaks, Cellular Starting Cells and Tissues), 등급(적정 제조 기준 등급, 연구용 등급), 최종사용자(제약·바이오테크놀러지 기업 최종사용자, 학술·연구기관 최종사용자, CMO·CRO 최종사용자)

조사 대상 기업의 예

  • AcceGen
  • AllCells
  • Anthony Nolan
  • ATCC(American Type Culture Collection)
  • BioIVT
  • Bio-Rad Laboratories, Inc.
  • Biospherix
  • CellGenix
  • CGT GLOBAL
  • Charles River Laboratories
  • Corning Incorporated
  • Excellos
  • Fisher Scientific
  • GE Healthcare(Cytiva)
  • Haplogen GmbH
  • HumanCells Bio
  • Lonza Group
  • Medpace
  • Merck KGaA
  • NMDP BioTherapies

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSA

Global Cellular Starting Materials Market to Reach US$5.0 Billion by 2030

The global market for Cellular Starting Materials estimated at US$1.5 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Cellular Starting Leukopaks, one of the segments analyzed in the report, is expected to record a 25.5% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Cellular Starting Cells & Tissues segment is estimated at 16.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$403.0 Million While China is Forecast to Grow at 20.5% CAGR

The Cellular Starting Materials market in the U.S. is estimated at US$403.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$760.8 Million by the year 2030 trailing a CAGR of 20.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 20.5% and 18.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.

Global Cellular Starting Materials Market - Key Trends & Drivers Summarized

How Are Cellular Starting Materials Revolutionizing Biotechnology?

Cellular starting materials serve as the foundation for a wide range of biopharmaceutical applications, including cell therapy, regenerative medicine, and vaccine development. These materials, which include stem cells, primary cells, and cell lines, are critical for advancing scientific research and producing innovative therapies for diseases such as cancer, autoimmune disorders, and neurodegenerative conditions. With the rapid expansion of precision medicine, the demand for high-quality and well-characterized cellular starting materials is increasing. Advancements in biotechnology and genetic engineering have further improved the scalability and reproducibility of cellular starting materials. Innovations in cell culture techniques, bioprocessing technologies, and cryopreservation methods are ensuring the stability and viability of these materials, making them more reliable for research and therapeutic applications. As the pharmaceutical and biotechnology sectors continue to evolve, cellular starting materials are becoming indispensable in the development of next-generation medical treatments.

Why Is the Demand for Cellular Starting Materials Increasing?

The rising prevalence of chronic and genetic diseases is driving the need for advanced cell-based therapies, fueling the demand for cellular starting materials. Researchers are leveraging these materials to develop personalized treatments that enhance patient outcomes by targeting specific genetic and molecular pathways. The growing focus on regenerative medicine, including stem cell therapies and tissue engineering, is further contributing to market expansion. Moreover, the increasing number of clinical trials in the field of cellular immunotherapy, gene therapy, and vaccine production is amplifying the demand for standardized and ethically sourced cellular starting materials. Regulatory agencies are emphasizing quality control and traceability in cellular material procurement, leading to advancements in sourcing, validation, and storage techniques. As cell-based research expands into new therapeutic areas, the need for reliable and scalable cellular starting materials will continue to grow.

Which Regions Are Leading the Cellular Starting Materials Market?

North America is currently the largest market for cellular starting materials, driven by strong investments in biotechnology, a well-established pharmaceutical industry, and extensive government support for biomedical research. The United States leads in cell-based therapy development, with numerous biotech firms and research institutions actively engaged in developing novel cell-based treatments. Europe follows closely, with countries like Germany, the UK, and France making significant advancements in cell therapy and regenerative medicine. The European Medicines Agency (EMA) has been actively involved in establishing regulatory frameworks for cell-based therapies, further strengthening market growth. Meanwhile, the Asia-Pacific region is experiencing rapid expansion due to increasing government initiatives, rising healthcare expenditures, and a growing number of clinical trials in Japan, China, and South Korea. These regions are expected to drive substantial market growth as cell-based research and therapy adoption increase.

What Are the Key Factors Driving Market Growth?

The growth in the Cellular Starting Materials market is driven by several factors, including advancements in stem cell research, increasing adoption of cell-based therapies, and the rising demand for regenerative medicine. The integration of artificial intelligence (AI) and automation in cell culture and quality control processes is improving efficiency and scalability, making cellular starting materials more accessible for research and therapeutic applications. Additionally, the expansion of biopharmaceutical manufacturing capabilities and the growing focus on precision medicine are propelling demand for high-quality cellular starting materials. The increasing number of strategic collaborations between research institutions, biotech firms, and pharmaceutical companies is further accelerating market growth. As cell-based treatments become more mainstream, the demand for reliable and ethically sourced cellular starting materials is expected to increase, shaping the future of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Cellular Starting Materials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Cellular Starting Leukopaks, Cellular Starting Cells and Tissues); Grade (Good Manufacturing Practices Grade, Research-Use Grade); End-Use (Pharmaceutical and Biotechnology Companies End-Use, Academic and Research Institutes End-Use, CMOs and CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AcceGen
  • AllCells
  • Anthony Nolan
  • ATCC (American Type Culture Collection)
  • BioIVT
  • Bio-Rad Laboratories, Inc.
  • Biospherix
  • CellGenix
  • CGT GLOBAL
  • Charles River Laboratories
  • Corning Incorporated
  • Excellos
  • Fisher Scientific
  • GE Healthcare (Cytiva)
  • Haplogen GmbH
  • HumanCells Bio
  • Lonza Group
  • Medpace
  • Merck KGaA
  • NMDP BioTherapies

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cellular Starting Materials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for High-Quality Starting Materials Propels Cell Therapy and Biomanufacturing Expansion
    • Standardization of Cell Sources Enhances Reproducibility and Downstream Processing
    • Increased Use of iPSCs and Primary Cells Fuels Specialized Starting Material Demand
    • Focus on Cell Line Stability and Genetic Integrity Strengthens Business Case for QC-Compliant Sources
    • Growth in Personalized Medicine Drives Custom and Patient-Derived Material Usage
    • Integration of Closed Systems and Aseptic Handling Enhances Regulatory Readiness
    • Expanding Applications in Immunotherapy and Regenerative Medicine Broadens Material Requirements
    • Strategic Sourcing of Donor-Derived Cells Supports Scale-Up of Allogeneic Therapies
    • Rising Adoption of Xeno-Free and Serum-Free Media Enhances Clinical Viability
    • Advancements in Cryopreservation Techniques Improve Supply Chain Resilience
    • Collaboration Between Biobanks and Therapy Developers Accelerates Commercialization
    • Increased Transparency and Traceability Strengthen GMP Compliance Across Supply Chains
    • Automation in Cell Isolation and Expansion Technologies Supports High-Throughput Needs
    • Growth of Contract Manufacturing Spurs Demand for Consistent Starting Material Supplies
    • Emergence of Ethical and Regulatory Frameworks Promotes Responsible Sourcing Practices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cellular Starting Materials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cellular Starting Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cellular Starting Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cellular Starting Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cellular Starting Leukopaks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cellular Starting Leukopaks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cellular Starting Leukopaks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cellular Starting Cells & Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cellular Starting Cells & Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cellular Starting Cells & Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Good Manufacturing Practices Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Good Manufacturing Practices Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Good Manufacturing Practices Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Research-Use Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Research-Use Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Research-Use Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for CMOs & CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Cellular Starting Materials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Cellular Starting Materials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of World 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제